An alligator can lose a foot in water thick enough to grow its own bacteria, then carry on almost as if nothing happened.

Injuries like that should be a death sentence. Territorial fights leave gators with torn limbs and open gashes, and they heal those wounds while marinating in warm, stagnant, microbially spectacular swamp water. Serious infection is rare. Biochemists noticed, and started drawing blood.

What the blood does in a test tube

Mark Merchant, a biochemist at McNeese State University in Louisiana, ran the obvious first experiment: does alligator serum kill things? In a 2003 paper in Comparative Biochemistry and Physiology, Merchant and colleagues reported that alligator serum suppressed growth in every bacterial strain they threw at it, while human serum managed roughly a third of them. After an hour, E. coli fared about ten times worse in gator serum than in human.

Two years later the same lab went after viruses. Writing in Antiviral Research, Merchant’s team found gator serum inhibited HIV-1, West Nile virus and herpes simplex type 1 in cell-based assays, with HIV-1 the most sensitive of the three. A 2006 study in Veterinary Immunology and Immunopathology then shifted attention from serum to white blood cells: acid extracts of alligator leukocytes knocked back 10 of 12 bacterial species and six of eight Candida yeasts, with moderate activity against HIV-1 and herpes.

Whatever did the damage proved to be small, heat-stable and destroyed by protein-chewing enzymes. That pointed at peptides, the short protein fragments that frogs, toads and Komodo dragons also use as chemical weapons.

Part of the appeal is architectural. Human defences lean heavily on antibodies, which have to be trained by exposure or vaccination before they are much use. Crocodilian defences lean the other way, on broad chemical weaponry that works on first contact with a microbe the animal has never met. A gator does not need to have seen a bacterium before to poison it.

Naming the molecules

So which molecule is actually doing the killing?

Finding activity in a fluid is easy compared with isolating the specific compound responsible, and that is where this work has ground forward slowly. Lancia Darville, then at Louisiana State University, presented early peptide-hunting results at an American Chemical Society meeting in 2008. Her work drew wide coverage, including in National Geographic, where she described the separation and identification of individual peptides as still in progress. Reporting at the time floated pills and creams reaching pharmacies within seven to ten years.

That timeline came and went. Molecular work continued anyway, and a team at George Mason University led by Monique van Hoek published a 2016 paper in BMC Microbiology characterising three peptides pulled from alligator plasma. They carry the workmanlike names Apo5, Apo6 and A1P. Two derive from alligator apolipoprotein C-1, a protein usually associated with shuffling fats around rather than with combat.

Their potency was comparable to LL-37, the best-studied human antimicrobial peptide, which makes them a plausible starting point instead of a novelty.

Why Acinetobacter matters here

Those target bacteria were not chosen at random. Van Hoek’s group tested the peptides against multi-drug-resistant and clinical isolates of Staphylococcus aureus, E. coli, Pseudomonas aeruginosa and Acinetobacter baumannii.

Acinetobacter is the one that makes infectious disease doctors tired. Carbapenem-resistant A. baumannii sits in the critical tier of the World Health Organization’s 2024 Bacterial Priority Pathogens List, published in The Lancet Infectious Diseases, alongside carbapenem-resistant Enterobacterales and rifampicin-resistant tuberculosis. It shrugs off last-resort drugs, thrives in intensive care wards and trades resistance genes with enthusiasm.

Alligators are not the only reptiles being mined, either. A Toronto group reported in the journal AIDS that potent HIV-1 inhibitors in saltwater crocodile plasma turned out to be histones, proteins normally busy spooling DNA inside the cell nucleus.

How far this sits from a pharmacy

Merchant is refreshingly blunt about the limits of his own findings. Asked in a Clinicians Roundtable interview what the HIV results mean for human medicine, he answered: for HIV, absolutely nothing. His reasoning is that the killing seen in whole serum comes largely from complement, a set of ten-odd large, unstable proteins that would provoke an immune reaction in people and would never survive on a shelf.

Peptides make a better bet, being small, synthesisable and easy to tweak.

Every result described here, though, is in vitro. Cells in plastic, not patients in beds. That same antiviral serum study flagged an awkward wrinkle of its own: at higher concentrations, alligator serum was toxic to the very mammalian cells used to run the assay. Antimicrobial peptides as a class have a long history of looking magnificent in a dish and then faltering inside a body, chewed up by enzymes, mopped up by blood proteins, or poisonous at the doses required to work.

None of that makes the biology less worth chasing. Two decades of experiments have moved this field from a broad observation that gator blood kills things to three sequenced peptides with measured activity against pathogens that are currently winning.

What happens next runs through the unglamorous middle stretch: years of medicinal chemistry between an interesting peptide and a compound that clears an infection without harming the patient. Most antimicrobial peptides have quietly died in there. Apo5 and its siblings have at least reached the starting line, which is further than most animal-derived leads ever get.